Psychopharmacology and Psychiatry Updates
by Psychopharmacology Institute
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 31 chart positions in 31 markets.
By chart position
- 🇺🇸US · Medicine#9930K to 100K
- 🇮🇳IN · Medicine#2730K to 100K
- 🇧🇷BR · Medicine#8810K to 30K
- 🇲🇽MX · Medicine#1361K to 10K
- 🇸🇪SE · Medicine#1571K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
62K to 214K🎙 Daily cadence·100 episodes·Last published 4d ago - Monthly Reach
Unique listeners across all episodes (30 days)
208K to 713K🇺🇸14%🇮🇳14%🇨🇱14%+28 more - Active Followers
Loyal subscribers who consistently listen
62K to 214K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
GLP-1 Agonists in Serious Mental Illness: Current Evidence
Aug 29, 2026
Unknown duration
Gabapentin, Topiramate & Baclofen in AUD
Aug 24, 2026
Unknown duration
Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good
Aug 19, 2026
Unknown duration
Disulfiram Unpacked: Efficacy, Risks, and Liver Safety
Aug 14, 2026
Unknown duration
GLP-1s and Lithium: What Clinicians Need to Know
Aug 9, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 8/29/26 | GLP-1 Agonists in Serious Mental Illness: Current Evidence | In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done? Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management? | — | ||||||
| 8/24/26 | Gabapentin, Topiramate & Baclofen in AUD | In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are most likely to benefit when first-line treatments have failed. Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Pharmacotherapy of Alcohol Use Disorder Gabapentin, Topiramate, and Baclofen for Alcohol Use Disorder | — | ||||||
| 8/19/26 | Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good | In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 Benzodiazepine Tapering: Key Takeaways From New Guidelines | — | ||||||
| 8/14/26 | Disulfiram Unpacked: Efficacy, Risks, and Liver Safety | In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations | — | ||||||
| 8/9/26 | GLP-1s and Lithium: What Clinicians Need to Know | In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 83 Can GLP-1 Agonists Elevate Lithium Levels? | — | ||||||
| 8/4/26 | Naltrexone for Alcohol Use Disorder: What You Should Know | In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't target abstinence still be a game-changer for your patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Naltrexone for Alcohol Use Disorder: Dosing, Monitoring, and Liver Safety | — | ||||||
| 7/30/26 | The OPTIMUM Trial: A Roadmap for Treatment-Resistant Depression in Late Life | In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when antidepressants fall short. When adding a medication outperforms switching entirely — and what that means for the patient sitting across from you — the answer may reshape your clinical approach. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 83 Antidepressant Augmentation vs. Switching in Geriatric Depression: Key Findings from the OPTIMUM Trial | — | ||||||
| 7/25/26 | Difficult-to-Treat Depression: First, Second, and Third-Line Strategies | In this episode, we explore what to do when antidepressants aren't working. How do you systematically approach a patient who isn't getting better — and when do you switch versus augment? Dr. Sagar Parikh walks through CANMAT's evidence-based framework for difficult-to-treat depression. Faculty: Sagar V. Parikh, M.D., F.R.C.P.C. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Rethinking Depression Treatment: An Update of CANMAT's Guidelines Pharmacologic Management of Difficult-to-Treat Depression: First, Second, and Third Line Options | — | ||||||
| 7/20/26 | high-dose olanzapinetreatment-resistant schizophrenia+3 | Oliver Freudenreich, M.D. | Psychopharmacology Institute | — | high-dose olanzapineclozapine+6 | — | 10m 32s | ||
| 7/15/26 | CANMAT guidelinescomplementary medicine+3 | Sagar V. Parikh, M.D., F.R.C.P.C. | St. John's wortsaffron+1 | — | CANMATdepression+6 | — | 7m 41s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 7/10/26 | xylazinetoxicology+3 | David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.David A. Gorelick | naloxonexylazine+1 | — | xylazinenaloxone+4 | — | 9m 20s | ||
| 7/5/26 | depression treatmentCANMAT guidelines+3 | Sagar V. Parikh, M.D. | CANMAT | — | depressiontreatment+5 | — | 18m 39s | ||
| 6/30/26 | deprescribingantipsychotics+3 | — | Psychopharmacology Institute | — | deliriumantipsychotics+3 | — | 14m 49s | ||
| 6/25/26 | long-acting injectablesschizophrenia treatment+3 | Brian Miller, M.D., Ph.D., M.P.H.Brian Miller | paliperidone palmitaterisperidone | — | paliperidonerisperidone+5 | — | 15m 02s | ||
| 6/20/26 | antipsychotic switchingclinical tips+3 | Oliver Freudenreich | Psychopharmacology Institute | — | antipsychoticsswitching+4 | — | 12m 01s | ||
| 6/15/26 | long-acting injectablesantipsychotics+3 | Brian Miller, M.D., Ph.D., M.P.H.Brian Miller | aripiprazoleolanzapine+4 | — | long-acting injectablesaripiprazole+4 | — | 11m 54s | ||
| 6/5/26 | schizophrenialong-acting injectable antipsychotics+3 | — | Psychopharmacology Institute | — | LAIsschizophrenia+5 | — | 7m 43s | ||
| 5/31/26 | Alzheimer's diseaselithium+4 | Scott Beach, M.D. | Lithium OrotateNature | — | lithiumAlzheimer's disease+5 | — | 11m 30s | ||
| 5/26/26 | Managing ADHD in Pregnancy: Weighing Risk versus Risk | In this episode, we explore the nuanced challenge of managing ADHD with stimulant medications during pregnancy. Is stopping the medication always the safer choice — or does untreated ADHD carry risks of its own? Dr. Amanda Koire breaks down the latest evidence to help clinicians make truly informed decisions. Faculty: Amanda Koire, M.D., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know Pregnancy, ADHD, and Stimulants: Making an Informed Choice | — | ||||||
| 5/21/26 | Ondansetron for Negative Symptoms of Schizophrenia | In this episode, we examine a surprising repurposing of ondansetron — a common antiemetic — as a potential adjunctive treatment for the notoriously hard-to-treat negative symptoms of schizophrenia. Could a nausea medication help restore motivation and emotional engagement in your patients with residual symptoms despite stable antipsychotic therapy? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 81 Is Ondansetron Effective for Negative Symptoms in Schizophrenia? | — | ||||||
| 5/16/26 | Managing SSRIs During Pregnancy: Myths vs. Evidence | In this episode, we explore how to manage SSRI treatment in pregnant patients — addressing common fears around fetal malformations, medication switching, and neonatal withdrawal. Can stopping an antidepressant actually do more harm than continuing it? Faculty: Amanda Koire, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know SSRI Treatment During Pregnancy: A Clinical Case | — | ||||||
| 5/11/26 | Rethinking Haloperidol's Cardiac Risk | In this episode, we explore a landmark meta-analysis that challenges decades of fear surrounding IV haloperidol and cardiac risk. Could one of medicine's most persistent myths be costing patients their best treatment option for delirium? Dr. Scott Beach breaks down the evidence. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 80 IV Haloperidol: Are Cardiac Safety Concerns Overblown? | — | ||||||
| 5/6/26 | Bipolar Disorder, Lithium, and Pregnancy: What the Evidence Says | In this episode, we explore the complex risk-versus-risk decision of using lithium during pregnancy and breastfeeding. How do you weigh the near-certainty of mood relapse against fetal cardiac risks? Dr. Amanda Koire provides a practical framework every clinician needs when managing bipolar disorder in reproductive-age women. Faculty: Amanda Koire, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know Lithium in Pregnancy and Breastfeeding | — | ||||||
| 5/1/26 | Clozapine Monitoring: New Guidelines for the Post-REMS Era | In this episode, we explore new international guidelines for clozapine monitoring following the FDA's REMS rescission. Should patients on stable clozapine continue lifelong monthly blood draws, or can we safely reduce monitoring after two years? Dr. Seeber discusses how these evidence-based recommendations balance patient burden with safety. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 79 New Guidelines for Clozapine ANC Monitoring | — | ||||||
| 4/26/26 | Prescribing Through Pregnancy: Dosing, Levels, and Relapse Risk | In this episode, we explore how pregnancy reshapes the pharmacokinetics of psychiatric medications — and what that means for your patients. Can stopping a mood stabilizer actually put a pregnancy at greater risk than continuing it? Dr. Amanda Koire breaks down the evidence. Faculty: Amanda Koire, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know Pregnancy's Impact on Medication Efficacy and Dosing Considerations | — | ||||||
Showing 25 of 100
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast
PsychRounds: The Psychiatry Podcast
Dr. Tanner Hewitt, Dr. Larry Wang and Dr. Bradley Miller
NEI Podcast
Neuroscience Education Institute
Psychiatry Boot Camp
Mark Mullen, MD
Psychiatry & Psychotherapy Podcast
David Puder, M.D.
Psychofarm Podcast
Psychiatry, Skepticism, and Integration.
PsychEd: Educational Psychiatry Podcast
PsychEd
Chart history for Psychopharmacology and Psychiatry Updates
Peaked at #7 in CL, top 10 in 2 of 34 tracked markets, currently #7 in CL.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| CL | — | #7 | #7 | — |
| NG | — | #9 | #9 | — |
| India | — | #27 | #27 | — |
| TH | — | #27 | #27 | — |
| ID | — | #27 | #27 | — |
| PT | — | #31 | #31 | — |
| PL | — | #32 | #32 | — |
| HU | — | #36 | #36 | — |
| South Africa | — | #53 | #53 | — |
| Finland | — | #63 | #63 | — |
| CL | — | #63 | #63 | — |
| SA | — | #77 | #77 | — |
| GR | — | #87 | #87 | — |
| VN | — | #87 | #87 | — |
| Brazil | — | #88 | #88 | — |
| Denmark | — | #89 | #89 | — |
| United States | — | #99 | #99 | — |
| CH | — | #102 | #102 | — |
| BE | — | #105 | #105 | — |
| NG | — | #105 | #105 | — |
Chart Positions
34 placements across 31 markets.
Chart Positions
34 placements across 31 markets.